[Genomic, molecular biology and malaria: new medical perspectives?].
The knowledge of genomic structure of man, of Plasmodium falciparum and of its main vector Anopheles gambiae has led to great progress in the understanding of malaria pathophysiology. It may also offer new perspectives for malaria therapy vaccines or control of mosquito-borne transmission. In pathophysiology, genes encoding adhesion plasmodial proteins of their receptors were identified, as well as other genes controlling the patient immune response or the antigenic parasite variability. From a therapeutic point of view, new targets for future antimalarial drugs were identified, mainly in apicoplast (a vestige of vegetal structure incorporated by the parasite during its phylogenic evolution) and several enzymes, particularly proteases. It will be now necessary among these "promising new molecules" to select a few ones (probably no more than 5 or 6) for a pre clinical and clinical pharmaceutical development. Indeed, the industrial possibilities for developing new antimalarial drugs are evidently limited and several other antimalarial drugs are already under development. For future malaria vaccines, several new targets and antigenic proteins were also identified. As for new drugs, a complete evaluation of these antigens is absolutely necessary to select few of them for clinical development. Particularly for malaria, ADN vaccines may offer very promising perspectives with the possibility to obtain both humoral and cellular immunity and to use at the same time a panel of plasmodial antigens. It could be thus possible to obtain a simultaneous immunization against different stages of Plasmodium falciparum (sporozoites, merozoites, gametocytes) and to use, as an adjuvant, a gene encoding a viral protein or a cytokine (GMCSF). In Anopheles gambiae genome, several genes encoding for key-proteins, particularly odorant receptors necessary for blood meals, were identified. Non biting-non transmitting mosquitoes were obtained by genetic manipulation and, from an academic viewpoint, offer a very attractive new perspective for the interruption of malaria transmission. Unfortunately several practical problems remain unsolved and genetically modified mosquitoes do not survive long enough among "wild" strains. On the whole genomic and proteomic gave very exciting scientific results in malaria and, very probably the post-genomic phase will even give more new data. From a practical, medical viewpoint, it is still too early and speculative to imagine their possible applications for malaria control.
P
P
Ambroise-Thomas
D000818:Animals; D023281:Genomics; D006801:Humans; D017780:Malaria Vaccines; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000469:parasitology* / Q000503:physiopathology / Q000517:prevention & control; D008967:Molecular Biology; D010963:Plasmodium falciparum / Q000235:genetics* / Q000276:immunology
D017780:Malaria Vaccines